Patents Issued in December 8, 2016
  • USE OF TIGHT JUNCTION ANTAGONISTS IN THE TREATMENT OF ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS
    Publication number: 20160355551
    Abstract: The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof.
    Type: Application
    Filed: August 12, 2016
    Publication date: December 8, 2016
    Inventors: Blake Paterson, Peter Ward, Alessio Fasano
  • METHODS AND COMPOSITIONS FOR RIBOSOMAL SYNTHESIS OF MACROCYCLIC PEPTIDES
    Publication number: 20160355552
    Abstract: Methods and compositions are provided for generating macrocyclic peptides from genetically encoded, ribosomally produced polypeptide precursors. Also provided are nucleic acid molecules, polypeptides, and methods for generating combinatorial libraries of macrocyclic peptides. These methods can be used to produce vast libraries of conformationally constrained peptide ligands as well as facilitate the functional screening of these libraries to identify compound(s) with desired activity properties.
    Type: Application
    Filed: December 23, 2014
    Publication date: December 8, 2016
    Inventor: Rudi Fasan
  • INFLUENZA VIRUS VACCINES AND USES THEREOF
    Publication number: 20160355553
    Abstract: The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein on or more amino acids in the HA2 domain have been mutated. Also provided are nucleic acids encoding the polypeptides, compositions comprising the polypeptides and/or nucleic acid molecules, as well as methods of their use, in particular in the detection, prevention and/or treatment of influenza.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 8, 2016
    Applicant: Janssen Vaccines & Prevention B.V.
    Inventors: Jan Willem Meijberg, Antonietta Impagliazzo, Ronald Vogels, Robert H.E. Friesen, Philippe Alard, Stefan Loverix, Katarina Radosevic
  • Fusobacterium polypeptides and methods of use
    Publication number: 20160355554
    Abstract: The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 8, 2016
    Inventors: Darren E. Straub, Daryll A. Emery
  • MIMOTOPES FOR USE IN IMMUNOTHERAPY FOR SHELLFISH AND/OR ARTHROPOD ALLERGY
    Publication number: 20160355555
    Abstract: The present invention provides isolated peptides and nucleic acids encoding the isolated peptides that can modify a subject's immune response to tropomyosin. The isolated peptides correspond to peptide epitope mimics that are based on an invertebrate tropomyosin allergen, e.g., the shrimp tropomyosin Met e 1. Also provided are compositions and methods of use thereof to reduce, minimize or eliminate an allergic response to arthropods and/or shellfish.
    Type: Application
    Filed: June 3, 2016
    Publication date: December 8, 2016
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE CHINESE UNIVERSITY OF HONG KONG
    Inventors: PATRICK LEUNG, KA HOU CHU, YEE YAN WAI, YAT HIN NICKI LEUNG
  • NOVEL NEUROPEPTIDES USEFUL AS INSECTICIDES
    Publication number: 20160355556
    Abstract: The invention provides short peptides derived from an insect neuropeptide for controlling insects, particularly peptides or their analogs derived from PBAN family neuropeptide having at least one dPhe residue. The invention further provides an environmentally friendly method for controlling and/or preventing insect infestation by applying the short peptides in very low concentrations.
    Type: Application
    Filed: September 21, 2014
    Publication date: December 8, 2016
    Inventor: Miriam Altstein Schwarz
  • SAXATILIN-FC FUSION PROTEIN AND USE THEREOF
    Publication number: 20160355557
    Abstract: The present invention relates to a saxatilin derivative having an increased half life and a use thereof. The saxatilin derivative of the present invention has thrombolytic ability similar to that of saxatilin, which is the mother protein, a remarkably increased protein half life, and efficiently dissolves, for long period of time, blood clots already formed in blood vessels of an animal model with a FeCl3-induced carotid by using the same. Therefore, a composition containing, as an active ingredient, the saxatilin derivative of the present invention does not cause reocclusion after penetration and effectively opens to microvessels, and is thus very useful for treating angiostenosis or occlusive diseases (for example, cerebrovascular diseases, cardiovascular diseases, arteriosclerotic vascular diseases, coronary artery diseases, and peripheral vascular diseases).
    Type: Application
    Filed: July 30, 2014
    Publication date: December 8, 2016
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Sung Yu HONG, Ji Hoe HEO, Il KWON, Dong Ik KIM, Yang Soo JANG, Young Dae KIM
  • Methods for Treatment of Nephrotic Syndrome and Related Conditions
    Publication number: 20160355558
    Abstract: The present disclosure provides a polypeptide and method for treating and/or preventing nephrotic syndrome, such as but not limited to those associated with minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.
    Type: Application
    Filed: September 15, 2015
    Publication date: December 8, 2016
    Inventor: Sumant S CHUGH
  • NORRIN REGULATION OF CELLULAR PRODUCTION OF JUNCTION PROTEINS AND USE TO TREAT RETINAL VASCULATURE EDEMA
    Publication number: 20160355559
    Abstract: A method of tightening inter-cellular junctions in retinal or choroidal vessel cells includes exposing the retinal or choroidal vessel cells to norrin. Upon sufficient contact time, for norrin to selectively up-regulate gene expression of VE-cadherin or claudin-5 in the retinal or choroidal vessel cells, the inter-cellular junctions are tightened. The method is also suitable for treating retinal pigment epithelial cells in wet macular degeneration.
    Type: Application
    Filed: June 8, 2015
    Publication date: December 8, 2016
    Inventors: Michael T. Trese, Antonio Capone, JR., Kimberly Drenser
  • NETRIN-1 AND DEPENDENCE RECEPTOR PROTEINS AND METHODS OF USE
    Publication number: 20160355560
    Abstract: Provided herein are fragments of Netrin-1 proteins, fragments of DCC proteins and NEO1 proteins, and antibodies to epitopes located within the fragments of Netrin-1, DCC, and/or NEO1. Also provided herein are methods for using the fragments and antibodies, including methods for inhibiting binding of Netrin-1 to an UNC5 protein, a DCC protein, and/or a NEO1 protein. Other methods provided herein include inducing apoptosis of a cell, and reducing formation of multimers of Netrin-1 proteins, and treating a subject having a cancer or at risk of having a cancer.
    Type: Application
    Filed: February 10, 2015
    Publication date: December 8, 2016
    Inventor: Jorg Stetefeld
  • Cell penetrating protein adaptor molecules and their application in research and medicine
    Publication number: 20160355561
    Abstract: Coupling proteins that make strong protein-protein interactions equipped with cell penetrating peptides (CPPs) provide a convenient and powerful method to perturb cell interiors; there are many potential payloads and a broad palette of selectively membrane permeable probes. In a preferred embodiment, the coupling protein will be calmodulin or a related calcium binding protein. In a preferred embodiment, the CPP will be TAT or another CPP. In a preferred embodiment, the coupling protein will release its payload after targeting to an interior compartment. Cargo proteins can be purified by affinity methods using the same tag that allows binding by the adaptor, enabling an integrated approach with ‘gains in both function and safety. Access to cell interior compartments has potential applications in research, diagnostics, and therapeutics.
    Type: Application
    Filed: June 3, 2015
    Publication date: December 8, 2016
    Inventor: John C. Salerno
  • STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE
    Publication number: 20160355562
    Abstract: The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.
    Type: Application
    Filed: June 10, 2016
    Publication date: December 8, 2016
    Inventors: Ulrich Sensfuss, Thomas Kruse, Jesper F. Lau
  • GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
    Publication number: 20160355563
    Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
    Type: Application
    Filed: August 16, 2016
    Publication date: December 8, 2016
    Inventors: Rasmus JUST, Kirsten Lindegaard BOVBJERG, Ditte RIBER, Wayne Shaun RUSSELL
  • METHOD TO DETECT AUTOANTIBODY REACTIVITY FOR DEAMIDATED INSULIN AUTOANTIGEN IN DIABETES
    Publication number: 20160355564
    Abstract: Provided herein are epitopes and mimotopes thereof useful in the diagnosis and treatment of type 1 diabetes (T1D), as well as antibodies recognizing such epitopes, and diagnostics, therapeutics, kits, and methods of use thereof.
    Type: Application
    Filed: May 11, 2016
    Publication date: December 8, 2016
    Inventors: Jing Jin, Xunrong Luo, Grazia Aleppo
  • DIAGNOSIS OF A NEUROAUTOIMMUNE DISEASE
    Publication number: 20160355565
    Abstract: A method for diagnosing a disease by detecting an autoantibody that binds to flotillin1 and/or flotillin2 in a sample, a polypeptide comprising flotillin1 and/or flotillin2 or a variant thereof, which may be immobilized, a method of treating a disease by applying to a subject the polypeptide that binds to an autoantibody, an autoantibody binding to flotillin1 and/or flotillin2, a method for isolating the autoantibody, a pharmaceutical composition, a medical device and test kit comprising the polypeptide, are provided. A method for detecting the presence of an autoantibody is also provided.
    Type: Application
    Filed: June 3, 2016
    Publication date: December 8, 2016
    Applicant: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
    Inventors: Winfried STOECKER, Lars Komorowski, Madeleine Scharf, Ramona Miske, Yvonne Denno, Inga-Madeleine Dettmann, Christian Probst, Stefanie Hahn, Stephanie Kade, George Trendelenburg
  • Novel Synthetic Biology-Based ADCC Technology
    Publication number: 20160355566
    Abstract: A novel synthetic biology-based ADCC technology is provided that enhances or enables ADCC response. The novel ADCC technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.
    Type: Application
    Filed: January 8, 2015
    Publication date: December 8, 2016
    Inventors: CHIANG J. LI, SHYAM UNNIRAMAN
  • MULTIMERIC IL-15 SOLUBLE FUSION MOLECULES AND METHODS OF MAKING AND USING SAME
    Publication number: 20160355567
    Abstract: The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.
    Type: Application
    Filed: July 19, 2016
    Publication date: December 8, 2016
    Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-ping Han
  • RECOMBINANT FACTOR VIII PROTEINS
    Publication number: 20160355568
    Abstract: Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.
    Type: Application
    Filed: February 15, 2013
    Publication date: December 8, 2016
    Applicant: BIOGEN IDEC MA INC.
    Inventor: John KULMAN
  • SURFACE, ANCHORED FC-BAIT ANTIBODY DISPLAY SYSTEM
    Publication number: 20160355569
    Abstract: The present invention provides, in part, an antibody display system that simultaneously uses a secretion and a display mode. A bait complexed with a monovalent antibody fragment can be expressed on the surface of the host cell wherein the fragment may be assayed for antigen binding while full antibody is simultaneously secreted from the host cell. Methods of using the system for identifying antibodies that bind specifically to an antigen of interest are also provided. Polypeptides, polynucleotides and host cells useful for making the antibody display system are also provided along with methods of use thereof.
    Type: Application
    Filed: May 25, 2016
    Publication date: December 8, 2016
    Inventors: Dougxing Zha, Hussam Hisham Shaheen
  • IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
    Publication number: 20160355570
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: June 30, 2016
    Publication date: December 8, 2016
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • LIBRARIES OF GENETIC PACKAGES COMPRISING NOVEL HC CDR1, CDR2, AND CDR3 AND NOVEL LC CDR1, CDR2, AND CDR3 DESIGNS
    Publication number: 20160355571
    Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.
    Type: Application
    Filed: June 8, 2016
    Publication date: December 8, 2016
    Applicant: Dyax Corp.
    Inventor: Robert Charles Ladner
  • SYSTEM, APPARATUS AND METHOD FOR BIOMOLECULES PRODUCTION
    Publication number: 20160355572
    Abstract: An automated method for the production of cells and/or biomolecules such as protein or peptides includes culturing cells in at least one high cell density bioreactor, thereby fluidly connecting said bioreactor with a culture medium supply and a gas or gaseous mixture; fluidly connecting said bioreactor with a downstream unit; and growing cells to a density at least 50 million cells per ml. The total volume of the bioreactor is at least 10 liters. A system suitable for implementation of the automated method above is a small-scale and cupboard-sized system, which can be placed in a portable clean room.
    Type: Application
    Filed: February 9, 2015
    Publication date: December 8, 2016
    Inventor: José Castillo
  • GENE THERAPY FOR ALZHEIMER'S AND OTHER NEURODEGENERATIVE DISEASES AND CONDITIONS
    Publication number: 20160355573
    Abstract: Gene therapy compositions and methods to inhibit or treat neurodegenerative diseases, e.g., Alzheimer's disease, are provided.
    Type: Application
    Filed: September 5, 2014
    Publication date: December 8, 2016
    Inventors: Ronald G. Crystal, Steven M. Paul
  • HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF
    Publication number: 20160355574
    Abstract: The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.
    Type: Application
    Filed: November 5, 2015
    Publication date: December 8, 2016
    Inventors: Arnon Rosenthal, Michael Leviten
  • OLIGOPEPTIDE AND METHODS FOR PRODUCING CONJUGATES THEREOF
    Publication number: 20160355575
    Abstract: The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid ? deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).
    Type: Application
    Filed: November 13, 2014
    Publication date: December 8, 2016
    Applicants: F. Hoffmann-La Roche AG, Centre National de la Recherche Scientifique, Commissariat A L'Energie Atomique et Aux Energies Alternatives
    Inventors: Pierre LAFAYE, Sylvie BAY, Benoit DELATOUR, Marc DHENAIN, Charles DUYCKAERTS, Tengfei LI, Matthias VANDESQUILLE, Christian CZECH, Fiona GRUENINGER
  • ANTIBODY-BASED THERAPY OF TRANSTHYRETIN (TTR) AMYLOIDOSIS AND HUMAN-DERIVED ANTIBODIES THEREFOR
    Publication number: 20160355576
    Abstract: Provided are novel human-derived antibodies specific for transthyretin (TTR), preferably capable of binding misfolded, misassembled, and/or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to anti-bodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.
    Type: Application
    Filed: December 22, 2014
    Publication date: December 8, 2016
    Inventors: Jan GRIMM, Aubin MICHALON
  • METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN
    Publication number: 20160355577
    Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Application
    Filed: May 12, 2016
    Publication date: December 8, 2016
    Applicant: GENENTECH, INC.
    Inventors: Robert F. Kelley, Marissa Matsumoto
  • METHODS OF TREATING A TAUOPATHY
    Publication number: 20160355578
    Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.
    Type: Application
    Filed: August 11, 2016
    Publication date: December 8, 2016
    Inventors: Irene GRISWOLD-PRENNER, Nancy E. Stagliano, Vu Cao Dang
  • METHODS FOR TREATING COMPLEMENT-ASSOCIATED DISORDERS
    Publication number: 20160355579
    Abstract: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 8, 2016
    Inventors: Russell P. Rother, Camille BEDROSIAN, Stephen P. SQUINTO, Leonard BELL
  • METHODS FOR TREATING COMPLEMENT-ASSOCIATED DISORDERS
    Publication number: 20160355580
    Abstract: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 8, 2016
    Inventors: Russell P. ROTHER, Camille BEDROSIAN, Stephen P. SQUINTO, Leonard BELL
  • COMPOSITIONS AND METHODS FOR TREATING AMYLOID PLAQUE ASSOCIATED SYMPTOMS
    Publication number: 20160355581
    Abstract: The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of A? plaque associated symptoms or for decreasing amyloid plaque loads. The method comprises administering an effective amount of an anti-ApoE antibody to a living mammalian biosystem such as to a human.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 8, 2016
    Inventors: David Holtzman, Jungsu KIM, Hong Jiang, Adam Eltorai
  • VHH FOR APPLICATION IN TISSUE REPAIR, ORGAN REGENERATION, ORGAN REPLACEMENT AND TISSUE ENGINEERING
    Publication number: 20160355582
    Abstract: The present invention relates to a VHH which binds to a growth factor or is an antagonist for a growth factor, or binds to an implant.
    Type: Application
    Filed: April 1, 2016
    Publication date: December 8, 2016
    Applicant: UNIVERSITEIT TWENTE
    Inventors: Hermanus Bernardus Johannes KARPERIEN, Cornelis Theodorus VERRIPS, Mohamed EL KHATTABI, Emilie DOOMS RODRIGUES, Jan DE BOER, Clemens Antoni VAN BLITTERSWIJK, Renee DE BRUIN
  • ANTIBODIES TARGETING BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS THEREFOR
    Publication number: 20160355583
    Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.
    Type: Application
    Filed: May 26, 2016
    Publication date: December 8, 2016
    Applicant: NOVARTIS AG
    Inventors: Zijun CHEN, Sujun DENG, Yun HE, Dagang HUANG, Markus KUGLER, Qian LI, Chris Xiangyang LU, Xiao LUO, Yongqiang SHAN, Kathrin Ulrike TISSOT-DAGUETTE, Jing WU
  • ANTIBODIES NEUTRALIZING GM-CSF FOR USE IN THE TREATMENT OF RHEUMATOID ARTHRITIS OR AS ANALGESICS
    Publication number: 20160355584
    Abstract: The invention relates to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of inflammatory disorders such as rheumatoid arthritis according to specific dosing regimen. The invention relates also to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of pain, e.g. pain experienced in inflammatory disorders such as rheumatoid arthritis, according to specific dosage regimen.
    Type: Application
    Filed: September 1, 2014
    Publication date: December 8, 2016
    Inventors: Thomas WAGNER, Malin CARLSSON, Margit STAUM KALTOFT
  • ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP
    Publication number: 20160355585
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
    Type: Application
    Filed: January 5, 2016
    Publication date: December 8, 2016
    Inventor: Jeffrey T.L. Smith
  • Covalent Diabodies and Uses Thereof
    Publication number: 20160355586
    Abstract: The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.
    Type: Application
    Filed: February 10, 2016
    Publication date: December 8, 2016
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang
  • ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20160355587
    Abstract: The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 4, 2016
    Publication date: December 8, 2016
    Inventors: James William West, Jason Gary Sagert, Jonathan Alexander Terrett, Annie Yang Weaver, Luc Roland Desnoyers, Shweta Singh
  • Bispecific CD3 and CD19 Antigen Binding Constructs
    Publication number: 20160355588
    Abstract: Bispecific antigen binding constructs are described that bind to CD3 and CD19 or CD20 antigens.
    Type: Application
    Filed: July 11, 2014
    Publication date: December 8, 2016
    Inventors: Gordon Yiu Kon Ng, Surjit Bhimarao Dixit, Thomas Spreter von Kreudenstein
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20160355589
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: August 17, 2015
    Publication date: December 8, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
  • LYM-1 AND LYM-2 TARGETED CAR CELL IMMUNOTHERAPY
    Publication number: 20160355590
    Abstract: CAR cells targeting and antibodies human HLA-DR are described as a new method of cancer treatment. It is proposed that HLA-DR CAR cells are safe and effective in patients and can be used to treat human tumors expressing the HLA-DR.
    Type: Application
    Filed: June 3, 2016
    Publication date: December 8, 2016
    Inventor: Alan L. Epstein
  • SUBCUTANEOUS ANTI-HLA-DR MONOCLONAL ANTIBODY FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES
    Publication number: 20160355591
    Abstract: The present invention concerns compositions and methods of use of anti-HLA-DR antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease. The subcutaneously administered anti-HLA-DR antibody is effective to treat hematologic cancer or autoimmune disease in patients that have relapsed from or are refractory to standard therapies for hematologic cancer or autoimmune disease, such as administration of anti-CD20 antibodies, such as rituximab.
    Type: Application
    Filed: August 18, 2016
    Publication date: December 8, 2016
    Inventors: David M. Goldenberg, William A. Wegener
  • ANTI-ITGA3 ANTIBODIES, ACTIVATABLE ANTI-ITGA3 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20160355592
    Abstract: The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 4, 2016
    Publication date: December 8, 2016
    Inventors: Jason Gary Sagert, Jonathan Alexander Terrett, Luc Roland Desnoyers, Shweta Singh, Annie Yang Weaver
  • ANTIBODY VACCINE CONJUGATES AND USES THEREFOR
    Publication number: 20160355593
    Abstract: The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (?hCG) antigen linked to an anti-mannose receptor (MR) antibody.
    Type: Application
    Filed: January 12, 2016
    Publication date: December 8, 2016
    Inventors: Tibor Keler, Michael Endres, Lizhen He, Venky Ramakrishna
  • METHODS AND COMPOSITIONS FOR MODULATING LYMPHANGIOGENESIS, E.G., TO TREAT TRANSPLANT REJECTION, IN A SUBJECT
    Publication number: 20160355594
    Abstract: Methods of modulating the occurrence of lymphangiogenesis in a subject are provided. In some instances, the method is a method of treating transplant rejection in the subject. Aspects of the methods include administering to the subject an effective amount of: a first antagonist for a tyrosine kinase receptor and a second antagonist for an integrin receptor. In some embodiments, the methods include enhancing survival of transplanted tissue in a subject. Aspects of the invention further include compositions, e.g., pharmaceutical compositions and kits that find use in methods of the invention.
    Type: Application
    Filed: June 13, 2016
    Publication date: December 8, 2016
    Inventor: Lu Chen
  • CX3CR1-BINDING POLYPEPTIDES
    Publication number: 20160355595
    Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.
    Type: Application
    Filed: August 22, 2016
    Publication date: December 8, 2016
    Inventors: Sanjaya SINGH, Alisa K. WATERMAN, Erik DEPLA, Toon LAEREMANS, Diane VAN HOORICK, Cedric Jozef Néotère VERVERKEN
  • METHOD OF USING ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40 TO TREAT IBD
    Publication number: 20160355596
    Abstract: A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.
    Type: Application
    Filed: March 9, 2015
    Publication date: December 8, 2016
    Inventors: Marek HONCZARENKO, Shah VAISHALI, Xiaoni LIU, Wendy L. TRIGONA, Rong SHI, Suzanne J. SUCHARD, Karen D. PRICE, Linda M. GUSTAVSON
  • METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES
    Publication number: 20160355597
    Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody. In some embodiments, the antibody is administered in a dose selected from about 0.2 mg, about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg.
    Type: Application
    Filed: June 7, 2016
    Publication date: December 8, 2016
    Applicant: Genentech, Inc.
    Inventors: Ina P. RHEE, Jeong KIM, Mahrukh HUSENI, Eric STEFANICH, Sid SUKUMARAN, Chi-Chung LI
  • Antibody molecules having specificity for human OX40
    Publication number: 20160355598
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: August 19, 2016
    Publication date: December 8, 2016
    Inventors: Alastair David Griffiths Lawson, Andrew Malcolm Nesbitt, Andrew George Popplewell, Stevan Graham Shaw, Diana Shpektor, Yi Zhang
  • ANTI-CD71 ANTIBODIES, ACTIVATABLE ANTI-CD71 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20160355599
    Abstract: The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 4, 2016
    Publication date: December 8, 2016
    Inventors: Jason Gary Sagert, Kimberly Ann Tipton, Jonathan Alexander Terrett, Shweta Singh, Annie Yang Weaver, Luc Roland Desnoyers
  • Trispecific antibodies
    Publication number: 20160355600
    Abstract: The invention provides trispecific antibodies that co-engage CD3, CD8 and a tumor target antigen.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 8, 2016
    Inventors: Gregory Moore, John Desjarlais, Seung Chu, Sung-Hyung Lee